Graft failure due to noncompliance among 628 kidney transplant recipients with long-term follow-up: A single-center observational study

Transplantation

Volumn 97, Issue 9, 2014, Pages 925-933

  Gaynor, Jeffrey J ^a   Ciancio, Gaetano ^a   Guerra, Giselle ^a   Sageshima, Junichiro ^a   Hanson, Lois ^a   Roth, David ^a   Chen, Linda ^a   Kupin, Warren ^a   Mattiazzi, Adela ^a   Tueros, Lissett ^a   Flores, Sandra ^a   Aminsharifi, Jason ^a   Joshi, Shivam ^a   Chediak, Zoila ^a   Ruiz, Phillip ^a   Vianna, Rodrigo ^a   Burke, George W ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Cause specific graft loss; Graft failure due to noncompliance; Kidney transplantation; Prognostic factors

Indexed keywords

ALEMTUZUMAB; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ADULT; AFRICAN AMERICAN; AGE DISTRIBUTION; ARTICLE; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; ETHNIC DIFFERENCE; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT FAILURE DUE TO NONCOMPLIANCE; GRAFT RECIPIENT; HISPANIC; HUMAN; INCIDENCE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; AGE; ETHNOLOGY; GRAFT REJECTION; KIDNEY FAILURE; MEDICATION COMPLIANCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGRESSION ANALYSIS; RISK; TREATMENT OUTCOME;

ADULT; AGE FACTORS; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; RENAL INSUFFICIENCY; RISK; TREATMENT OUTCOME;

EID: 84903778093     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000438199.76531.4a     Document Type: Article

References (53)

1. Schweitzer EJ, Matas AJ, Gillingham KF, et al. Causes of renal allograft loss: progress in the 1980's, challenges for the 1990's. Ann Surg 1991; 214: 679.
2. Pirsch JD, Ploeg RJ, Gange S, et al. Determinants of graft survival after renal transplantation. Transplantation 1996; 61: 1581.
3. Terasaki PI, Gjertson DW, Cecka JM, et al. Significance of the donor age effect on kidney transplants. Clin Transplant 1997; 11: 366.
4. Pascual M, Theruvath T, Kawai T, et al. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346: 580.
5. El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9: 527.
6. Howard RJ, Patton PR, Reed AI, et al. The changing causes of graft loss and death after kidney transplantation. Transplantation 2002; 73: 1923.
7. Gjertson DW, Dabrowska DM, Cui X, et al. Four causes of cadaveric kidney transplant failure: a competing risk analysis. Am J Transplant 2002; 2: 84.
8. Ponticelli C, Villa M, Cesana B, et al. Risk factors for late kidney al-lograft failure. Kidney Int 2002; 62: 1848.
9. Parasuraman R, Abouljoud M, Jacobsen G, et al. Increasing trend in infection-related death-censored graft failure in renal transplantation. Transplantation 2011; 91: 94.
10. Didlake RH, Dreyfus K, Kerman RH, et al. Patient noncompliance: a major cause of late graft failure in cyclosporine-treated renal transplants. Transplant Proc 1988; 20: 63.
11. Dunn J, Golden D, Van Buren CT, et al. Causes of graft loss beyond two years in the cyclosporine era. Transplantation 1990; 49: 349.
12. Bergmann LS, Roper L, Bow LM, et al. Causes of late graft failure in cadaveric renal transplantation. Transplant Proc 1993; 25: 1340.
13. Gaston RS, Hudson SL, Ward M, et al. Late renal allograft loss: noncompliance masquerading as chronic rejection. Transplant Proc 1999; 31: 21S.
14. Matas AJ, Humar A, Gillingham KJ, et al. Five preventable causes of kidney graft loss in the 1990s: a single-center analysis. Kidney Int 2002; 62: 704
15. Michelon TF, Piovesan F, Pozza R, et al. Noncompliance as a cause of renal graft loss. Transplant Proc 2002; 34: 2768.
16. Butler JA, Roderick P, Mullee M, et al. Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review. Transplantation 2004; 77: 769.
17. Dunn TB, Browne BJ, Gillingham KJ, et al. Selective retransplant after graft loss to nonadherence: success with a second chance. Am J Transplant 2009; 9: 1337.
18. Sellares J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012; 12: 388.
19. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allo-graft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004; 4: 1289.
20. Keith DS, deMattos A, Golconda M, et al. Factors associated with improvement in deceased donor renal allograft function in the 1990s. J Am Soc Nephrol 2005; 16: 1512.
21. Djamali A, Samaniego M, Muth B, et al. Medical care of kidney transplant recipients after the first posttransplant year. Clin J Am Soc Nephrol 2006; 1: 623.
22. McCullough KP, Keith DS, Meyer KH, et al. Kidney and pancreas transplantation in the United States, 1998-2007: access for patients with diabetes and end-stage renal disease. Am J Transplant 2009; 9: 894.
23. Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011; 11: 450.
24. Segev DL. Renal allograft survival: getting better all the time. Am J Transplant 2011; 11: 422.
25. Stegall MD, Park WD, Dean PG, et al. Improving long-term renal allo-graft survival via a road less traveled by. Am J Transplant 2011; 11: 1382.
26. Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378.
27. Guerra G, Ciancio G, Gaynor JJ, et al. Randomized trial of immu-nosuppressive regimens in renal transplantation. J Am Soc Nephrol 2011; 22: 1758.
28. Rovelli M, Palmeri D, Vossler E, et al. Noncompliance in renal transplant recipients: evaluation by socioeconomic groups. Transplant Proc 1989; 21: 3979.
29. Rovelli M, Palmeri D, Vossler E, et al. Noncompliance in organ transplant recipients. Transplant Proc 1989; 21: 833.
30. Ghods AJ, Nasrollahzadeh D, Argani H. Risk factors for non-compliance to immunosuppressive medications in renal transplant recipients. Transplant Proc 2003; 35: 2609.
31. Takemoto SK, Pinsky BW, Schnitzler MA, et al. A retrospective analysis of immunosuppression compliance, dose reduction and discontinuation in kidney transplant recipients. Am J Transplant 2007; 7: 2704.
32. Pinsky BW, Takemoto SK, Lentine KL, et al. Transplant outcomes and economic costs associated with patient noncompliance to immuno-suppression. Am J Transplant 2009; 9: 2597.
33. Frazier P, Davis-Ali S, Dahl K. Correlates of noncompliance among renal transplant recipients. Clin Transplant 1994; 8: 550.
34. Sketris I, Waite N, Grobler K, et al. Factors affecting compliance with cy-closporine in adult renal transplant patients. Transplant Proc 1994; 26: 2538.
35. Greenstein S, Siegal B. Compliance and noncompliance in patients with a functioning renal transplant: a multicenter study. Transplantation 1998; 66: 1718.
36. Raiz LR, Kilty KM, Henry ML, et al. Medication compliance following renal transplantation. Transplantation 1999; 68: 51.
37. Schweizer RT, Rovelli M, Palmeri D, et al. Noncompliance in organ transplant recipients. Transplantation 1990; 49: 374.
38. Butkus DE, Meydrech EF, Raju SS. Racial differences in the survival of cadaveric renal allografts: overriding effects of HLA matching and socioeconomic factors. N Engl J Med 1992; 327: 840.
39. Kiley DJ, Lam CS, Pollak R. A study of treatment compliance following kidney transplantation. Transplantation 1993; 55: 51.
40. Nevins TE, Kruse L, Skeans MA, et al. The natural historyofazathioprine compliance after renal transplantation. Kidney Int 2001; 60: 1565.
41. Weng FL, Israni AK, Joffe MM, et al. Race and electronically measured adherence to immunosuppressive medications after deceased donor renal transplantation. J Am Soc Nephrol 2005; 16: 1839.
42. Couzi L, Moulin B, Morin MP, et al. Factors predictive of medication nonadherence after renal transplantation: a French observational study. Transplantation 2013; 95: 326.
43. Foster BJ, Dahhou M, Zhang X, et al. Association between age and graft failure rates in young kidney transplant recipients. Transplantation 2011; 92: 1237.
44. Gondos A, Dohler B, Brenner H, et al. Kidney graft survival in Europe and the United States: strikingly different long-term outcomes. Transplantation 2013; 95: 267.
45. Woodward RS, Page TF, Soares R, et al. Income-related disparities in kidney transplant graft failures are eliminated by Medicare's immu-nosuppression coverage. Am J Transplant 2008; 8: 2636.
46. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance im-munosuppression) vs. daclizumab in renal transplantation at 24 months of follow up. Clin Transplant 2008; 22: 200.
47. Ciancio G, Gaynor JJ, Roth D, et al. Randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in living donor renal transplantation. Transplant Proc 2010; 42: 3503.
48. Ciancio G, Gaynor JJ, Zarak A, et al. Randomized trial of mycophenolate mofetil vs. enteric-coated mycophenolate sodium in primary renal transplantation with tacrolimus and steroid avoidance: four-year analysis. Transplantation 2011; 91: 1198.
49. Ciancio G, Gaynor JJ, Sageshima J, et al. Randomized trial of dual antibody induction therapy with steroid avoidance in renal transplantation. Transplantation 2011; 92: 1348.
50. Prentice RL, Kalbfleisch JD, Peterson A, et al. The analysis of failure times in the presence of competing risks. Biometrics 1978; 34: 541.
51. Gaynor JJ, Feuer EJ, Tan CC, et al. On the use of cause-specific failure and conditional failure probabilities: examples from clinical oncology data. J Am Stat Assoc 1993; 88: 400.
52. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496.
53. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Statist Med 2007; 26: 2389.